Canntab Therapeutics Limited (CSE: PILL.CN)(OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or " Canntab "), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein , currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022 . Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who... Read More

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the " Company " or " Canntab ") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including... Read More

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the " Company " or " Canntab ") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that that it has changed its auditor from MNP LLP (the " Former Auditor ") to Clearhouse LLP (the " Successor Auditor "). The Former Auditor resigned effective May 27, 2022 , at the Company's request, and the... Read More

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the " Company " or " Canntab ") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with... Read More

Signs Affiliate Program with OnPharm-United with over 600 pharmacies in Ontario Receives approval from the Province of Saskatchewan to begin sales Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or " Canntab " ), a leading innovator in cannabinoid and terpene blends in hard pill form... Read More

Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1) (the "Company" or "Canntab"), a leading innovator of cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce a strategic planning collaboration and commercial partnership to create an Indigenous Opiate and Illicit... Read More

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the official launch of its online e-commerce platform and web site at www.Canntab.ca . The E-Commerce... Read More

The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the future Levitee Labs and Canntab Therapeutics have executed a services agreement resulting in Levitee Labs informing patients about the Canntab portfolio of therapeutics Levitee Labs will offer the entire Canntab product lineup throughout all its... Read More

Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the " Company " or " Canntab "), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product deliveries for Ontario and Australia . On January 7, 2022 Canntab... Read More

Agreement with Levitee to service over 35,000 annual patient visits with the aim to help treat their patients with substance use addictions and chronic pain Levitee Labs will offer the entire Canntab product lineup throughout all its clinics and pharmacies in Alberta and British Columbia Canntab Therapeutics Limited (CSE:... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab" ) the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has entered into a service agreement (the "Agreement") with Pathway Health Corporation... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab" ), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has received its medical sales license from Health Canada for its Markham, Ontario... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or " Canntab "), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the " Agreement ") with 36Eight Technologies Inc. (" 36Eight... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of 1,679,000 warrants into... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or " Canntab "), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick , the Company's Co-Founder, Director and... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License. Further to an announcement made on... Read More

3 rd Patent Grant with Australia following the United States and Canada Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited Participation in Australia's Largest Cannabis Research Study Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or "... Read More

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE:TBF1) (the " Company " or " Canntab "), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2 nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets... Read More

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the " Company " or " Canntab "), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announced today that it has engaged Independent Trading Group Inc. (" ITG ") to provide market-making services to the Company. ITG will trade the Company's common shares (the " Common Shares ") on the Canadian Securities... Read More

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or " Canntab "), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office (" CIPO ") has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23,... Read More